<DOC>
	<DOCNO>NCT00143312</DOCNO>
	<brief_summary>To prevent recurrence invasive fungal infection patient allogeneic stem cell transplant</brief_summary>
	<brief_title>Voriconazole Secondary Prophylaxis Invasive Fungal Infections Patients With Allogeneic Stem Cell Transplants</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients proven probable IFI previous 12 month receive allogenic stem cell transplant haematological disease Pregnant lactate woman Severe disease tham underlie condition Active , symptomatic uncontrolled Invasive Fungal Infection Any evidence active fungal disease define MSGEORTC criterion Concomitant use Voriconazole 36 hour chemotherapy 48 hour chemotherapy Other medical condition , include HIV positive serology would interfere evaluation therapeutic response safety study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Invasive Fungal Infection , Allogenic Stem Cell Transplant , prophylaxis , leukemia , voriconazole</keyword>
</DOC>